Join to View Full Profile
UNC Hospitals101 Manning DrChapel Hill, NC 27514
Dr. Levandowski is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- eRNA production and p53 activity
Education & Training
University of North Carolina HospitalsResidency, Internal Medicine, 2022 - 2024
University of Colorado School of Medicine Anschutz Medical CampusClass of 2022, MD
University of Colorado BoulderPhD, Biochemistry, 2014 - 2020- Davidson CollegeBS, Biology, 2004 - 2008
Certifications & Licensure
NC State Medical License 2022 - 2025
Publications & Presentations
PubMed
- 2 citationsMediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancers.Daniel P Nussbaum, Colin A Martz, Andrew M Waters, Alejandro Barrera, Annie Liu
NPJ Precision Oncology. 2024-05-31 - 2 citationsMediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS-Mutant Cancers.Kris Wood, Daniel Nussbaum, Colin Martz, Andrew Waters, Alejandro Barrera
Research Square. 2023-11-02 - 7 citationsSuppression of p53 response by targeting p53-Mediator binding with a stapled peptide.Benjamin L Allen, Kim Quach, Taylor Jones, Cecilia B Levandowski, Christopher C Ebmeier
Cell Reports. 2022-04-05
Journal Articles
- Suppression of p53 response by targeting p53–Mediator binding with a stapled peptide.Allen, B.L., Quach, K., Levandowski, C.B., Jones, T., Ebmeier, C.C., Rubin, J.D., Read, T., Dowell, R.D., Schepartz, A., Taatjes, D.J., Cell Reports
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
